Our findings identify an additional mechanism of impaired NO bioavailability in severe falciparum malaria and pose an additional challenge to NOS-based adjunctive interventions to increase NO bioavailability in severe malaria. The gene discussed is NOS2; the disease is Plasmodium falciparum malaria.